Skip to main content
. 2019 Mar 20;317(5):F1274–F1284. doi: 10.1152/ajprenal.00616.2018

Fig. 3.

Fig. 3.

Effect of IL-2 treatment on systemic lupus erythematosus (SLE) disease activity. A: anti-dsDNA IgG measured at 34 wk of age in control and SLE mice. Plasma levels of anti-dsDNA IgG were higher in SLE mice than in control mice, but IL-2 treatment had no effect on anti-dsDNA levels. *P < 0.05 vs. vehicle- and IL-2-treated control groups. B: plasma IgG concentrations measured at 34 wk of age in control and SLE mice. IgG concentrations were higher in SLE mice compared with control mice, and IL-2 treatment had no effect on IgG concentration. *P < 0.05 vs. vehicle- and IL-2-treated control groups. C: circulating activated T cells as measured by flow cytometry. Mice treated with IL-2 had lower levels of CD4+CD69+ T cells than vehicle-treated mice. *P < 0.05 vs. the vehicle-treated SLE group. D: CD69+ T cells in the spleen. No differences were detected between the groups. P values were generated using one-way ANOVA followed by a Tukey’s post test for multiple comparisons.